JP4057091B2 - 細菌株、及び該細菌株を含む薬学的組成物、並びに胆汁酸に関しての変化した代謝に関連するか、引き起こされる疾患を治療するための、上記組成物の使用 - Google Patents

細菌株、及び該細菌株を含む薬学的組成物、並びに胆汁酸に関しての変化した代謝に関連するか、引き起こされる疾患を治療するための、上記組成物の使用 Download PDF

Info

Publication number
JP4057091B2
JP4057091B2 JP05367397A JP5367397A JP4057091B2 JP 4057091 B2 JP4057091 B2 JP 4057091B2 JP 05367397 A JP05367397 A JP 05367397A JP 5367397 A JP5367397 A JP 5367397A JP 4057091 B2 JP4057091 B2 JP 4057091B2
Authority
JP
Japan
Prior art keywords
cultures
microorganismes
bile
strains
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP05367397A
Other languages
English (en)
Japanese (ja)
Other versions
JPH1086A (ja
Inventor
レナータ・マリア・アンナ・カバリエレ・ベセリー
クラウディオ・デ・シモーネ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
RENATA MARIA ANNA CAVALIERE VESELY
Original Assignee
RENATA MARIA ANNA CAVALIERE VESELY
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11373572&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP4057091(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by RENATA MARIA ANNA CAVALIERE VESELY filed Critical RENATA MARIA ANNA CAVALIERE VESELY
Publication of JPH1086A publication Critical patent/JPH1086A/ja
Application granted granted Critical
Publication of JP4057091B2 publication Critical patent/JP4057091B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/225—Lactobacillus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/46—Streptococcus ; Enterococcus; Lactococcus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP05367397A 1996-03-11 1997-03-07 細菌株、及び該細菌株を含む薬学的組成物、並びに胆汁酸に関しての変化した代謝に関連するか、引き起こされる疾患を治療するための、上記組成物の使用 Expired - Lifetime JP4057091B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT96MI000468A IT1283225B1 (it) 1996-03-11 1996-03-11 Ceppi di batteri, composizione farmaceutica contenente uno o piu' di tali ceppi e uso dei medesimi per la prevenzione e la terapia delle
IT96A000468 1996-03-11

Publications (2)

Publication Number Publication Date
JPH1086A JPH1086A (ja) 1998-01-06
JP4057091B2 true JP4057091B2 (ja) 2008-03-05

Family

ID=11373572

Family Applications (1)

Application Number Title Priority Date Filing Date
JP05367397A Expired - Lifetime JP4057091B2 (ja) 1996-03-11 1997-03-07 細菌株、及び該細菌株を含む薬学的組成物、並びに胆汁酸に関しての変化した代謝に関連するか、引き起こされる疾患を治療するための、上記組成物の使用

Country Status (13)

Country Link
US (6) US6225104B1 (enExample)
EP (1) EP0795604B1 (enExample)
JP (1) JP4057091B2 (enExample)
KR (1) KR100472061B1 (enExample)
CN (1) CN1110547C (enExample)
AT (1) ATE246509T1 (enExample)
CA (1) CA2198518C (enExample)
DE (1) DE69723898T2 (enExample)
DK (1) DK0795604T3 (enExample)
ES (1) ES2200145T3 (enExample)
IT (1) IT1283225B1 (enExample)
MX (1) MX9701816A (enExample)
PT (1) PT795604E (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1283225B1 (it) * 1996-03-11 1998-04-16 Renata Maria Anna Ve Cavaliere Ceppi di batteri, composizione farmaceutica contenente uno o piu' di tali ceppi e uso dei medesimi per la prevenzione e la terapia delle
IT1309427B1 (it) 1999-05-28 2002-01-23 Mendes S U R L Composizione dietetica o farmaceutica utile per la prevenzione o iltrattamento dell'iperossaluria e suo uso
IT1306716B1 (it) * 1999-06-21 2001-10-02 Mendes S U R L Associazione di batteri lattici e suo uso per la prevenzione e/o iltrattamento terapeutico di infezioni e di stati infiammatori.
ITRM20010763A1 (it) * 2001-12-21 2003-06-21 Simone Claudio De Nuovo ceppo di batterio lattico e composizioni commestibili, farmaci e prodotti veterinari che lo contengono.
US7374606B2 (en) * 2003-06-27 2008-05-20 Canon Kabushiki Kaisha Water-based ink and ink recording method
CN1882605B (zh) * 2003-11-21 2012-07-11 陶氏环球技术公司 使用Sec-系统分泌的改进的表达系统
CN1663573B (zh) * 2004-03-04 2010-04-28 青岛东海药业有限公司 一种稳定安全的微生态制剂及其制备方法和用途
EP1736164A4 (en) * 2004-03-31 2009-06-24 Calpis Co Ltd AGENT TO PREVENT OR REMOVE HEPATOPATHY AND FUNCTIONAL FEED TO PREVENT OR DELETE HEPATOPATHY
CA2677179C (en) * 2007-01-31 2016-02-16 Dow Global Technologies Inc. Bacterial leader sequences for increased expression
SI2266619T1 (sl) * 2008-03-04 2015-11-30 Dikovskiy, Aleksander Vladimirovich Farmacevtski sestavek na osnovi hepatoprotektorja in prebiotika, njegova izdelava in uporaba
US12268718B2 (en) 2012-01-16 2025-04-08 Labyrinth Holdings Llc Control of cellular redox levels
US20140086849A1 (en) 2012-09-21 2014-03-27 Elizabeth McKenna Naturally-Occurring CpG Oligonucleotide Compositions and Therapeutic Applications Thereof
AU2013209887B2 (en) 2012-01-16 2021-02-18 Elizabeth Mckenna Compositions and methods for the treatment of hepatic diseases and disorders
EP3172973B1 (en) * 2015-11-27 2020-04-08 DAFLORN Ltd. Probiotic formula, process of its preparation and use
CA3008195A1 (en) * 2015-12-14 2017-06-22 Metabogen Ab Treatment of intrahepatic cholestasis and related liver diseases
CN115569141B (zh) * 2022-10-17 2023-10-20 中国农业科学院兰州兽医研究所 脱氧胆酸在制备抗口腔链球菌产品中的应用
WO2025094993A1 (ja) * 2023-10-31 2025-05-08 国立大学法人大阪大学 Ｍａｉｔ細胞リガンドの同定のための細胞、および当該細胞を用いるｍａｉｔ細胞リガンドのスクリーニング方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1221734B (it) * 1983-02-24 1990-07-12 Schiena Michele Giuseppe Di Ursodesossicolico solfato acido sale sodico
US5079240A (en) * 1990-03-15 1992-01-07 The Regents Of The University Of California Synthetic conjugated bile acid and method of use thereof
US5716615A (en) * 1992-02-10 1998-02-10 Renata Maria Anna Cavaliere Vesely Dietary and pharmaceutical compositions containing lyophilized lactic bacteria, their preparation and use
IT1255241B (it) * 1992-07-22 1995-10-20 Simos Contos Derivato di acido biliare e suo uso in terapia
JP2992945B2 (ja) * 1994-03-11 1999-12-20 カルピス株式会社 ラクトバチルス・アシドフィルス乳酸菌
IT1283225B1 (it) * 1996-03-11 1998-04-16 Renata Maria Anna Ve Cavaliere Ceppi di batteri, composizione farmaceutica contenente uno o piu' di tali ceppi e uso dei medesimi per la prevenzione e la terapia delle
EP0856259B1 (en) * 1996-12-23 1998-08-12 SITIA-YOMO S.p.A. Composition for feed use comprising lyophilized live lactic bacteria
IT1309427B1 (it) * 1999-05-28 2002-01-23 Mendes S U R L Composizione dietetica o farmaceutica utile per la prevenzione o iltrattamento dell'iperossaluria e suo uso
ITRM20010763A1 (it) * 2001-12-21 2003-06-21 Simone Claudio De Nuovo ceppo di batterio lattico e composizioni commestibili, farmaci e prodotti veterinari che lo contengono.
TWI241912B (en) * 2002-10-30 2005-10-21 Food Industry Res & Dev Inst Novel Acid-and bile salt-resistant Lactobacillus isolates having the ability to lower and assimilate cholesterol

Also Published As

Publication number Publication date
US20040259227A1 (en) 2004-12-23
PT795604E (pt) 2003-12-31
ES2200145T3 (es) 2004-03-01
EP0795604B1 (en) 2003-08-06
US20110217759A1 (en) 2011-09-08
EP0795604A3 (en) 1998-04-15
DE69723898T2 (de) 2004-01-29
DE69723898D1 (de) 2003-09-11
USRE41276E1 (en) 2010-04-27
CN1110547C (zh) 2003-06-04
JPH1086A (ja) 1998-01-06
KR100472061B1 (ko) 2005-07-08
US7959911B2 (en) 2011-06-14
CA2198518A1 (en) 1997-09-11
DK0795604T3 (da) 2003-10-27
ITMI960468A0 (enExample) 1996-03-11
CA2198518C (en) 2010-04-13
ITMI960468A1 (it) 1997-09-11
EP0795604A2 (en) 1997-09-17
ATE246509T1 (de) 2003-08-15
US6225104B1 (en) 2001-05-01
CN1165857A (zh) 1997-11-26
US20030082791A1 (en) 2003-05-01
IT1283225B1 (it) 1998-04-16
KR970065708A (ko) 1997-10-13
MX9701816A (es) 1998-04-30
US20010012629A1 (en) 2001-08-09

Similar Documents

Publication Publication Date Title
US20110217759A1 (en) Strains of bacteria and pharmaceutical composition containing one or more of such strains and use of same for preventing and treating diseases associated with or caused by altered metabolism of bile acids
Lewis et al. Modification of bile acids by intestinal bacteria
Thomas et al. Mechanism for the transit-induced increase in colonic deoxycholic acid formation in cholesterol cholelithiasis
Gallaher et al. Probiotics, Cecal Microflora, and Aberrant Crypts in the Rat Colon1, 2
Mastromarino et al. Metabolic epidemiology of colon cancer: enzymic activity of fecal flora
Koo et al. Long‐term effect of bifidobacteria and neosugar on precursor lesions of colonic cancer in CF1 mice
Dickinson et al. Determination of bile acid conversion potencies of intestinal bacteria by screening in vitro and subsequent establishment in germfree rats
Li et al. Effect of feeding of a cholesterol-reducing bacterium, Eubacterium coprostanoligenes, to germ-free mice
DE60124131T2 (de) Verwendung eines lactobacillus-stammes zur verringerung der risikofaktoren im zusammenhang mit dem metabolischen syndrom
KR100934747B1 (ko) 새로운 젖산균 균주, 이를 함유하는 식용 조성물, 약물 및수의학적 제품
MXPA97001816A (en) Bacterials and pharmaceutical composition containing such strains and using the same to prevent and treat diseases associated with metabolism altered biliary deactives or caused by my
JPS60149527A (ja) 生体内脱臭剤
CN109069548A (zh) 肝内胆汁淤积及相关肝疾病的治疗
DE60002194T3 (de) Zusammensetzung enthaltend alkalische sphingomyelase von bakteriellem ursprung zum gebrauch als diätetische zusammensetzung, nahrungsergänzungsmittel oder pharmazeutisches produkt
EP2266619B1 (de) Pharmazeutische zusammensetzung auf basis eines leberschützenden mittels und eines präbiotischen mittels, ihre herstellung und verwendung
Yanahira et al. Effects of lactitol-oligosaccharides on the intestinal microflora in rats
Prabha et al. Bacterial transformations of bile acids
KR20230088249A (ko) 생체 직교성 클릭 화학을 통한 외재성 프로바이오틱스의 장내 집락화용 조성물 및 키트
Hashimoto et al. Effects of β-lactam antibiotics on intestinal microflora and bile acid metabolism in rats
CN117625588A (zh) 一种治疗非酒精性脂肪肝的活菌复合物
Sauer et al. In patients with orthotopic liver transplantation, serum markers of cholestasis are unreliable indicators of biliary secretion
ROY et al. Clinical implications of bile acids in paediatrics
US20230201360A1 (en) Composition and Kit for colonization in gut of external probiotics through bioorthogonal click chemistry
CN106974939B (zh) 厚壁菌类益生菌在治疗和预防肥胖及其相关疾病中的应用
JP4572185B2 (ja) 酪酸菌及び／又は乳酸菌を含有してなる消化管洗浄助剤

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20061024

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070124

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20070403

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20070703

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20070706

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20071003

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20071113

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20071213

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20101221

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20111221

Year of fee payment: 4

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20111221

Year of fee payment: 4

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20121221

Year of fee payment: 5

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20131221

Year of fee payment: 6

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term